Skip to main content
. 2012 May 24;17(6):747–755. doi: 10.1634/theoncologist.2011-0458

Table 1.

Prospective clinical trials of octreotide for neuroendocrine tumors

graphic file with name onc00612-1074-t01.jpg

aMedian duration of treatment includes all drug regimens.

Abbreviations: ECOG, Eastern Cooperative Oncology Group; GEP, gastroenteropancreatic; KPS, Karnofsky performance status; LAR, long-acting repeatable; NET, neuroendocrine tumor; NS, not stated; pNET, pancreatic neuroendocrine tumor; PS, performance status.